European equities traded in the US as American depositary receipts were tracking lower late Wednesday morning, falling 0.84% to 1,466.92 on the S&P Europe Select ADR Index.
From continental Europe, the gainers were led by biopharmaceutical company DBV Technologies (DBVT) and medical device maker EDAP TMS (EDAP), which rose 4.4% and 2.9% respectively. They were followed by internet browser company Opera (OPRA) and oil and gas company TotalEnergies (TTE), which were up 1.1% and 0.9%.
The decliners from continental Europe were led by semiconductor company Sequans Communications (SQNS) and pharmaceutical company Ascendis Pharma (ASND), which lost 6.5% and 4.4% respectively. They were followed by pharmaceutical company Novo Nordisk (NVO) and Spanish lender Banco Bilbao Vizcaya Argentaria (BBVA), which dropped 4.2% and 3.5%.
From the UK and Ireland, the gainers were led by biopharmaceutical companies Amarin (AMRN) and Mereo BioPharma Group (MREO), which increased 4% and 1.8% respectively. They were followed by insurance firm Prudential (PUK) and lender HSBC (HSBC), which edged 0.6% and 0.4% higher respectively.
The decliners from the UK and Ireland were led by biopharmaceutical company Adaptimmune Therapeutics (ADAP) and biotech firm Autolus Therapeutics (AUTL), which lost 3.3% and 3.1% respectively. They were followed by communications company WPP (WPP) and biotech firm Trinity Biotech (TRIB), which shed 3% and 2.6% respectively.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.